Immunohistochemical study of the proliferating ability and malignant potential of transitional cell carcinoma in the human urinary bladder

International Journal of Urology

Volumn 3, Issue S1, 1996, Pages

  Yoshikawa, Hiroyasu ^a   Ikeuchi, Takao ^b   Kai, Yoshio ^b  

^a Yokohama General Hospital   (Japan)

^b SHOWA UNIVERSITY FUJIGAOKA HOSPITAL   (Japan)

Author keywords

C erbB 2; Immunohistochemical method; P53; Proliferating cell nuclear antigen; Transitional cell carcinoma

Indexed keywords

CYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN P53; TP53 PROTEIN, HUMAN; TUMOR MARKER;

AGED; ARTICLE; BLADDER; BLADDER TUMOR; C-ERBB-2; CANCER GRADING; CANCER STAGING; CELL PROLIFERATION; FEMALE; HUMAN; IMMUNOHISTOCHEMICAL METHOD; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; TRANSITIONAL CELL CARCINOMA; ADULT; CLINICAL ARTICLE; CONFERENCE PAPER; HISTOPATHOLOGY; HUMAN TISSUE; ONCOGENE C ERB; PRIORITY JOURNAL;

C-ERBB-2; IMMUNOHISTOCHEMICAL METHOD; P53; PROLIFERATING CELL NUCLEAR ANTIGEN; TRANSITIONAL CELL CARCINOMA;

AGED; CARCINOMA, TRANSITIONAL CELL; CELL PROLIFERATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROLIFERATING CELL NUCLEAR ANTIGEN; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 0030481490     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.1996.tb00079.x     Document Type: Article

References (14)

1. The Japanese Urological Association, The Japanese Pathological Society. General Rules for Clinical and Pathological Studies on Bladder Cancer. 1st ed. Tokyo: Kanehara, 1980.
2. Miyachi K, Fritzler MJ, Tan EM: Autoantibody to a nuclear antigen in proliferating cells. J Immunol 1978; 121: 2228-2234.
3. Bravo R, Frank R, Blundell PA, MacDonald-Bravo H. Cyclin' PCNA is the auxiliary protein of DNA polymerase-5. Nature 1987; 326: 515-517.
4. Lee SH, Ishimi Y, Kenny MK, Bullock P, Dean FB, Hurwitz J. An inhibitor of the in vitro elongation reaction of simian virus 40 DNA replication is overcome by proliferating cell nuclear antigen. Proc Natl Acad Sci USA 1988; 85: 9469-9473.
5. Wada T, Shimabukuro T, Kurisu H, Shameem IA, Yoshihiro S, Matsuyama H, Naito K, Hashimoto O, Tanaka K. Expression of proliferating cell nuclear antigen in superficial bladder cancer. Acta Urol Jpn 1993; 39: 313-319.
6. Finiay CA, Hinds PW, Levine AJ. The p53 proto-oncogene can act as a suppressor of transformation. Cell 1989; 57: 1083-1093.
7. Baker SJ, Preisinger AC, Jessup JM, Paraskeve C, Markowitz S, Willson JKV, Hamilton S, Vogelstein B: p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res 1990; 50: 7717-7722.
8. Fujimoto K, Yamada Y, Okajima E, Kakizoe T, Sasaki H, Sugimura T, Terada M. Frequent association of p53 gene mutation in invasive bladder cancer. Cancer Res 1992; 52: 1393-1398.
9. Miyamoto H, Kubota Y, Shuin T, Torigoe S, Hosaka M, Iwasaki Y, Danenberg K, Danenberg PV. Analysis of p53 gene mutations in primary human bladder cancer. Oncol Res 1993; 5: 245-249.
10. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire RL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182.
11. Venter DJ, Tsui NL, Kumarr S, Gullick WJ. Overexpression of the c-erbB-2 oncoprotein in human breast carcinomas: immunohistological assessment correlates with gene amplification. Lancet 1987; 2: 69-72.
12. Zhou D, Battifora H, Yokota J, Yamamoto T, Clive MJ. Association of multiple copies of the c-erbB-2 oncogene with the spread of breast cancer. Cance Res 1987; 47: 6123-6125.
13. Coombs LM, Pigott DA, Sweeney E, Proctor AJ, Eydmann ME, Perkinson C, Knowles MA. Amplification and over-expression of c-erbB-2 in transitional cell carcinoma of the urinary bladder. Br J Cancer 1991; 63: 601-608.
14. Kimura M, Tomita Y, Nishiyama T, Sato S, Ohmori K. Expression of epidermal growth factor receptor and c-erbB-2 product in transitional cell carcinoma. J Jpn Soc Cancer Ther 1992; 27: 1132-1138.